Michael King
Stock Analyst at EF Hutton
(0.80)
# 3,848
Out of 4,944 analysts
116
Total ratings
34.43%
Success rate
-15.72%
Average return
Main Sectors:
Top Industries:
Stocks Rated by Michael King
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| APLM Apollomics | Maintains: Buy | $1,100 → $650 | $5.87 | +10,973.25% | 4 | Apr 1, 2024 | |
| SONN Sonnet BioTherapeutics Holdings | Assumes: Buy | $1,179 | $3.95 | +29,753.16% | 7 | Aug 23, 2023 | |
| LTRN Lantern Pharma | Reiterates: Buy | $11 | $4.76 | +131.09% | 10 | Aug 10, 2023 | |
| BMEA Biomea Fusion | Reiterates: Buy | $32 | $1.72 | +1,760.47% | 11 | Jun 26, 2023 | |
| JSPR Jasper Therapeutics | Reiterates: Buy | $69 | $2.97 | +2,206.40% | 10 | Jun 12, 2023 | |
| COEP Coeptis Therapeutics Holdings | Assumes: Buy | $200 | $11.00 | +1,718.18% | 7 | May 25, 2023 | |
| HOWL Werewolf Therapeutics | Assumes: Buy | $8.3 | $1.35 | +514.81% | 6 | May 25, 2023 | |
| REGN Regeneron Pharmaceuticals | Reiterates: Buy | $862 | $561.55 | +53.50% | 11 | May 1, 2023 | |
| EXEL Exelixis | Reiterates: Buy | $24 | $38.49 | -37.65% | 10 | Apr 28, 2023 | |
| AGEN Agenus | Reiterates: Buy | $166 | $4.54 | +3,556.39% | 8 | Mar 28, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Buy | $42 | $7.72 | +444.04% | 5 | Feb 24, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Buy | $304 | $432.52 | -29.71% | 2 | Feb 24, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $123 → $116 | $11.00 | +954.55% | 6 | Feb 24, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $10 | $3.10 | +232.26% | 2 | Dec 16, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $24 | $31.98 | -24.95% | 1 | Mar 23, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $1,000 → $800 | $0.48 | +165,257.59% | 2 | Mar 11, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $43 → $46 | $20.74 | +121.85% | 3 | Mar 8, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $98 → $96 | $36.61 | +162.22% | 6 | Mar 3, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $36 | $0.71 | +4,937.08% | 1 | Jan 10, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $25 → $31 | $11.98 | +158.76% | 2 | Nov 5, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Market Outperform | $33 → $36 | $646.60 | -94.43% | 2 | Nov 13, 2017 |
Apollomics
Apr 1, 2024
Maintains: Buy
Price Target: $1,100 → $650
Current: $5.87
Upside: +10,973.25%
Sonnet BioTherapeutics Holdings
Aug 23, 2023
Assumes: Buy
Price Target: $1,179
Current: $3.95
Upside: +29,753.16%
Lantern Pharma
Aug 10, 2023
Reiterates: Buy
Price Target: $11
Current: $4.76
Upside: +131.09%
Biomea Fusion
Jun 26, 2023
Reiterates: Buy
Price Target: $32
Current: $1.72
Upside: +1,760.47%
Jasper Therapeutics
Jun 12, 2023
Reiterates: Buy
Price Target: $69
Current: $2.97
Upside: +2,206.40%
Coeptis Therapeutics Holdings
May 25, 2023
Assumes: Buy
Price Target: $200
Current: $11.00
Upside: +1,718.18%
Werewolf Therapeutics
May 25, 2023
Assumes: Buy
Price Target: $8.3
Current: $1.35
Upside: +514.81%
Regeneron Pharmaceuticals
May 1, 2023
Reiterates: Buy
Price Target: $862
Current: $561.55
Upside: +53.50%
Exelixis
Apr 28, 2023
Reiterates: Buy
Price Target: $24
Current: $38.49
Upside: -37.65%
Agenus
Mar 28, 2023
Reiterates: Buy
Price Target: $166
Current: $4.54
Upside: +3,556.39%
Feb 24, 2023
Reiterates: Buy
Price Target: $42
Current: $7.72
Upside: +444.04%
Feb 24, 2023
Reiterates: Buy
Price Target: $304
Current: $432.52
Upside: -29.71%
Feb 24, 2023
Maintains: Buy
Price Target: $123 → $116
Current: $11.00
Upside: +954.55%
Dec 16, 2022
Initiates: Buy
Price Target: $10
Current: $3.10
Upside: +232.26%
Mar 23, 2022
Initiates: Buy
Price Target: $24
Current: $31.98
Upside: -24.95%
Mar 11, 2022
Maintains: Buy
Price Target: $1,000 → $800
Current: $0.48
Upside: +165,257.59%
Mar 8, 2022
Maintains: Buy
Price Target: $43 → $46
Current: $20.74
Upside: +121.85%
Mar 3, 2022
Maintains: Buy
Price Target: $98 → $96
Current: $36.61
Upside: +162.22%
Jan 10, 2022
Initiates: Buy
Price Target: $36
Current: $0.71
Upside: +4,937.08%
Nov 5, 2021
Maintains: Buy
Price Target: $25 → $31
Current: $11.98
Upside: +158.76%
Nov 13, 2017
Maintains: Market Outperform
Price Target: $33 → $36
Current: $646.60
Upside: -94.43%